Raymond J. Louie

Raymond J. Louie

Auto-generated profile, based on publicly available information

Raymond J. Louie

Greenwood Genetic Center Greenwood South Carolina USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2019 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
ESElliot S. Stolerman
Elliot S. Stolerman
EFElizabeth Francisco
Elizabeth Francisco
JSJennifer L. Stallworth
Jennifer L. Stallworth
JJJulie R. Jones
Julie R. Jones
KMKristin G. Monaghan
Kristin G. Monaghan
RLRaymond J. Louie
Raymond J. Louie

4 May 2021 in Human Genetics
Verified
Journal Article
Open access
PDF file
IPIlaria Parenti
Ilaria Parenti
DLDaphné Lehalle
Daphné Lehalle
CNCaroline Nava
Caroline Nava
ETErin Torti
Erin Torti
ELElsa Leitão
Elsa Leitão
CMCyril Mignot
Cyril Mignot
Located in the critical 1p36 microdeletion region, the chromodomain helicase DNA-binding protein 5 (CHD5) gene encodes a subunit of the nucleosome remodeling and deacetylation (NuRD) complex required for neuronal development. Pathogenic variants in six of nine chromodomain (CHD) genes cause autosomal dominant neurodevelopmental disorders, while CHD5-related disorders are still unknown. Thanks to GeneMatcher and international collaborations, we assembled a cohort of 16 unrelated individuals harboring heterozygous CHD5 variants, all identified by exome sequencing. Twelve patients had de novo CHD5 variants, including ten missense and two splice site variants. Three familial cases had nonsense or missense variants segregating with speech delay, learning disabilities, and/or craniosynostosis. One patient carried a frameshift variant of unknown inheritance due to unavailability of the father. The most common clinical features included language deficits (81%), behavioral symptoms (69%), intellectual disability (64%), epilepsy (62%), and motor delay (56%). Epilepsy types were variable, with West syndrome observed in three patients, generalized tonic–clonic seizures in two, and other subtypes observed in one individual each. Our findings suggest that, in line with other CHD-related disorders, heterozygous CHD5 variants are associated with a variable neurodevelopmental syndrome that includes intellectual disability with speech delay, epilepsy, and behavioral problems as main features.

20 March 2017 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
RLRaymond J. Louie
Raymond J. Louie
QTQueenie K.‐G. Tan
Queenie K.‐G. Tan
JGJennifer B. Gilner
Jennifer B. Gilner
RRR. Curtis Rogers
R. Curtis Rogers
NYNoelle Younge
Noelle Younge
MFMichael J. Friez
Michael J. Friez

27 October 2022 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
CSCharles E. Schwartz
Charles E. Schwartz
RLRaymond J. Louie
Raymond J. Louie
ATAnnick Toutain
Annick Toutain
CSCindy D. Skinner
Cindy D. Skinner
MFMichael J. Friez
Michael J. Friez
RSRoger E. Stevenson
Roger E. Stevenson

29 May 2021 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
WBWilliam Burns
William Burns
LBLynne M. Bird
Lynne M. Bird
DHDelphine Heron
Delphine Heron
BKBoris Keren
Boris Keren
DRDivya Ramachandra
Divya Ramachandra
MLMichael J. Lyons
Michael J. Lyons

20 March 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MPMercè Padró
Mercè Padró
RLRaymond J. Louie
Raymond J. Louie
BLBrian V. Lananna
Brian V. Lananna
AKAdam Krieg
Adam Krieg
LTLuika A. Timmerman
Luika A. Timmerman
DCDenise A. Chan
Denise A. Chan
About 75–80% of breast tumors express the estrogen receptor alpha (ER-α) and are treated with endocrine-target therapeutics, making this the premier therapeutic modality in the breast cancer clinic. However, acquired resistance is common and about 20% of resistant tumors loose ER-α expression via unknown mechanisms. Inhibition of ER-α loss could improve endocrine therapeutic efficacy, benefiting a significant number of patients. Here we test whether tumor hypoxia might commonly produce ER-α loss. Using standard molecular and cellular biological assays and a work station/incubator with controllable oxygen levels, we analyze the effects of hypoxia on ER-α protein, mRNA, and transcriptional activity in a panel of independently-derived ER-α positive cell lines. These lines were chosen to represent the diverse genetic backgrounds and mutations commonly present in ER-α positive tumors. Using shRNA-mediated knockdown and overexpression studies we also elucidate the role of hypoxia-inducible factor 1-alpha (HIF-1α) in the hypoxia-induced decrease in ER-α abundance. We present the first comprehensive overview of the effects of bona fide low environmental oxygen (hypoxia) and HIF-1α activity on ER-α abundance and transcriptional activity. We find that stabilized HIF-1α induces rapid loss of ER-α protein in all members of our diverse panel of breast cancer cell lines, which involves proteolysis rather than transcriptional repression. Reduced ER-α severely attenuates ER-α directed transcription, and inhibits cell proliferation without overt signs of cell death in the cell lines tested, despite their varying genomic backgrounds. These studies reveal a common hypoxia response that produces reduced ER-α expression and cell cycle stalling, and demonstrate a common role for HIF-1α in ER-α loss. We hypothesize that inhibitors of HIF-1α or the proteasome might stabilize ER-α expression in breast tumors in vivo, and work in combination with endocrine therapies to reduce resistance. Our data also suggests that disease re-occurrence in patients with ER-α positive tumors may arise from tumor cells chronically resident in hypoxic environments. We hypothesize that these non-proliferating cells may survive undetected until conditions change to oxygenate the environment, or cells eventually switch to proliferation via other signaling pathways.